Tolerance to NeuroEPO in Parkinson Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 1, 2015

Primary Completion Date

February 11, 2016

Study Completion Date

January 1, 2017

Conditions
Parkinson Disease
Interventions
DRUG

NeuroEPO

NeuroEPO \[CIMAB S.A, Havana, Cuba\]

Trial Locations (2)

11300

Centro Inmunologia Molecular CIM, La Habana

Unknown

Clinic of Movement Disorders, International Center for Neurological Restoration, Havana

All Listed Sponsors
collaborator

Center of Molecular Immunology, Cuba

OTHER

collaborator

University of Electronic Science and Technology of China

OTHER

lead

International Center for Neurological Restoration, Cuba

OTHER

NCT04110678 - Tolerance to NeuroEPO in Parkinson Disease | Biotech Hunter | Biotech Hunter